Pathophysiology of ldl
Role of ldl in atherosclerosis
Why does ldl cause plaque.
Non-Statin Lipid Lowering Agents
This table provides an overview of various non-statin lipid-lowering agents, summarizing their mechanisms, lipid-lowering efficacy, impact on major adverse cardiovascular events (MACE), advantages, and disadvantages.
Drug Classes Covered:
- Bempedoic Acid
- Inclisiran
- PCSK9 Inhibitors (Evolocumab, Alirocumab)
- Ezetimibe
- Bile Acid Sequestrants
- Niacin
- Fibrates
- Omega-3 Fatty Acids (EPA)
Each agent shows unique attributes in lipid lowering, cardiovascular impact, and side effect profiles.
Notably:
- PCSK9 inhibitors and Inclisiran provide substantial LDL-C reduction.
- Fibrates and Omega-3 fatty acids show greater triglyceride reduction benefits, useful in hypertriglyceridemia.
- Bempedoic Acid and Ezetimibe offer alternatives to statins, especially for those with statin-associated muscle symptoms.
Produced by: Dr.
Natalie Marreromed
Reviewed by: Dr. Patrick Zakka
CardioNerds Infographics
Explore our comprehensive colle
